IKNA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs...

Stats
Today's Volume	151 600
Average Volume	432 787
Market Cap	62.25M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.400 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.790
ATR14	$0.00500 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Germa Caroline	Buy	579 100	Stock Option (Right to Buy)
2024-02-29	Germa Caroline	Buy	0
2024-02-01	Ecsedy Jeffrey	Buy	100 000	Stock Option (Right to Buy)
2024-02-01	Marango Jotin	Buy	181 000	Stock Option (Right to Buy)
2024-02-01	Manfredi Mark	Buy	320 000	Stock Option (Right to Buy)

INSIDER POWER
95.73
Last 94 transactions
Buy: 20 809 745 \| Sell: 873 348

Volume Correlation

Long: -0.02 (neutral)

Short: -0.21 (neutral)

Signal:(49.648) Neutral

Ikena Oncology, Inc. Correlation

10 Most Positive Correlations
RMRM	0.946
APOP	0.919
CMPO	0.909
XLRN	0.907
CVT	0.903
BRACU	0.902
NVCN	0.9
PAIC	0.896
WTMA	0.894
TRHC	0.889

10 Most Negative Correlations
BOCH	-0.939
MMAC	-0.917
NETE	-0.902
NAKD	-0.893
HFWA	-0.892
SYBT	-0.882
VIEW	-0.879
GRIN	-0.878
RPRX	-0.878
AHPI	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ikena Oncology, Inc. Correlation - Currency/Commodity

0.53
( weak )

0.46
( neutral )

0.00
( neutral )

-0.33
( neutral )

Ikena Oncology, Inc. Financials

Annual	2023
Revenue:	$9.16M
Gross Profit:	$8.14M (88.86 %)
EPS:	$-1.630

Q4	2023
Revenue:	$659 000
Gross Profit:	$354 000 (53.72 %)
EPS:	$-0.410

Q3	2023
Revenue:	$1.19M
Gross Profit:	$943 000 (79.58 %)
EPS:	$-0.400

Q2	2023
Revenue:	$2.00M
Gross Profit:	$1.42M (70.76 %)
EPS:	$-0.440

Financial Reports:

No articles found.

Ikena Oncology, Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.